2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-18697
    JD-5037 1392116-14-1 ≥98.0%
    JD-5037 is a potent CB1R antagonist with an IC50 of 1.5 nM.
    JD-5037
  • HY-N0033
    Poliumoside 94079-81-9 99.80%
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity.
    Poliumoside
  • HY-N0457
    Chicoric acid 6537-80-0 99.95%
    Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects.
    Chicoric acid
  • HY-P99625
    Frexalimab 2515463-86-0 ≥99.0%
    Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research.
    Frexalimab
  • HY-113325
    NADP 53-59-8 99.70%
    NADP is a coenzyme involved in cellular electron transfer reactions in biological metabolism, which is alternately oxidized (NADP+) and reduced (NADPH), and can maintain cellular redox homeostasis and regulate many biological events, including cellular metabolism. NADPH is a universal electron donor that provides reducing ability for synthetic metabolic reactions and redox balance. NADPH plays a multifunctional role in regulating inflammation, redox homeostasis, and synthetic metabolism processes.
    NADP
  • HY-119412
    Biliatresone 1801433-90-8 99.48%
    Biliatresone is a natural toxin isolated from Dysphania glomulifera and D. littoralis. Biliatresone, a 1,2-diaryl-2-propenone class of isoflavonoid, produces extrahepatic biliary atresia in a zebrafish model.
    Biliatresone
  • HY-B1511A
    Cyclic AMP sodium 37839-81-9 ≥98.0%
    Cyclic AMP (Cyclic adenosine monophosphate) sodium, adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP sodium is an important second messenger in many biological processes.
    Cyclic AMP sodium
  • HY-122663A
    BIO8898 99.88%
    BIO8898 is a potent CD40-CD154 inhibitor. BIO8898 inhibits soluble CD40L binding to CD40-Ig with an IC50 value of 25 µM. BIO8898 inhibits CD40L-induced apoptosis.
    BIO8898
  • HY-112166
    (E)-Rilzabrutinib 1575596-29-0 99.37%
    Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM.
    (E)-Rilzabrutinib
  • HY-126255
    SBI-797812 2237268-08-3 99.88%
    SBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD+ in mice.
    SBI-797812
  • HY-13525
    CP-91149 186392-40-5 99.80%
    CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study.
    CP-91149
  • HY-15295
    Vonoprazan Fumarate 881681-01-2
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease.
    Vonoprazan Fumarate
  • HY-N0110
    Palmatine chloride 10605-02-4 99.81%
    Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
    Palmatine chloride
  • HY-P3375
    Mazdutide 2259884-03-0 99.74%
    Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D).
    Mazdutide
  • HY-107725
    BIBO3304 191868-14-1 99.95%
    BIBO3304 is a potent, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist, with subnanomolar affinity for both the human and the rat Y1 receptor (IC50=0.38 and 0.72 nM, respectively).
    BIBO3304
  • HY-108241
    (Z)-PUGNAc 132489-69-1 ≥99.0%
    (Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.
    (Z)-PUGNAc
  • HY-112489
    FSG67 1158383-34-6 99.95%
    FSG67 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor with an IC50 of 24 μM.
    FSG67
  • HY-17437A
    Mefloquine hydrochloride 51773-92-3 99.98%
    Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research.
    Mefloquine hydrochloride
  • HY-N0184A
    Dipotassium glycyrrhizinate 68797-35-3 99.68%
    Dipotassium glycyrrhizinate is a HMGB1 inhibitor, inhibits atopic dermatitis-related gene expression with anti-anti-inflammatory activity.
    Dipotassium glycyrrhizinate
  • HY-N1428C
    Ferric citrate 3522-50-7 ≥98.0%
    Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research.
    Ferric citrate
Cat. No. Product Name / Synonyms Application Reactivity